m+Medelevator.RU
← Поиск публикаций
World journal of critical care medicine · 2026

Myoclonus associated with tranexamic acid administration in a patient on veno-arterial extracorporeal membrane oxygenation support: A case report.

Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Dimitriadis Fotios, Pitsolis Theodoros, Kolovou Kyriaki, Maragoulia Sissy, Theodorou Evangelia, Konstantinou Giorgos, Soulele Theodora, Vlahodimitris Ioannis, Zervos Michail, Salata Paraskevi, Elaiopoulos Dimitrios, Gatzonis Stergios, Dimopoulos Stavros

Аннотация

BACKGROUND: Tranexamic acid (TXA) is widely used as an antifibrinolytic agent to reduce bleeding in cardiac and extracorporeal circulation settings. Neurological adverse effects, including seizures and myoclonus, are rare and not well documented in patients supported by extracorporeal membrane oxygenation (ECMO).

CASE SUMMARY: We report the case of a 52-year-old male with ST-elevation myocardial infarction and severe left ventricular dysfunction, who was transferred to our intensive care unit department under veno-arterial (VA)-ECMO support and continuous renal replacement therapy (CRRT). To maintain ECMO oxygenator function and due to decreasing fibrinogen levels, endovenous one gram TXA twice a day was administered and within hours after the second dose, the patient developed generalized myoclonic jerks. A non-contrast brain computed tomography revealed no acute or chronic abnormalities, and neurological evaluation attributed the findings to TXA as the most likely cause due to TXA overdose. Following discontinuation of TXA, the symptoms resolved within 48 hours.

CONCLUSION: This case highlights a rare neurological complication associated with TXA overdose, occurring in patient with VA-ECMO and CRRT. Clinicians should remain vigilant for such adverse effects in this context.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты